Connect Biopharma Ownership Update
Ticker: CNTB · Form: SC 13D/A · Filed: Jul 1, 2024 · CIK: 1835268
Sentiment: neutral
Topics: ownership-change, sec-filing, biotech
TL;DR
HUANG/PANACEA NOW HOLD 10.1% OF CONNECT BIOPHARMA AFTER FILING AMENDMENT 2.
AI Summary
On July 1, 2024, James Huang and Panacea Venture Healthcare Fund II, L.P. filed an amendment (No. 2) to their Schedule 13D regarding Connect Biopharma Holdings Limited. The filing indicates a change in beneficial ownership, with the group now holding 10,000,000 ordinary shares, representing approximately 10.1% of the outstanding shares. This filing follows a previous amendment on June 28, 2024.
Why It Matters
This filing signals a potential shift in control or influence over Connect Biopharma Holdings Limited by major shareholders, which could impact strategic decisions and stock performance.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership by significant holders can indicate strategic shifts or potential activism, warranting close monitoring.
Key Numbers
- 10.1% — Ownership Stake (Represents the beneficial ownership of James Huang and Panacea Venture Healthcare Fund II, L.P. in Connect Biopharma Holdings Limited as of July 1, 2024.)
- 10,000,000 — Ordinary Shares (The total number of ordinary shares beneficially owned by the filing group.)
Key Players & Entities
- James Huang (person) — Filing party and beneficial owner
- Panacea Venture Healthcare Fund II, L.P. (company) — Filing party and beneficial owner
- Connect Biopharma Holdings Limited (company) — Subject company
- 10,000,000 (dollar_amount) — Number of ordinary shares held
- 10.1% (dollar_amount) — Percentage of outstanding shares held
FAQ
What is the primary purpose of this SC 13D/A filing?
This filing is an amendment (No. 2) to a Schedule 13D, indicating a change in the beneficial ownership of Connect Biopharma Holdings Limited by James Huang and Panacea Venture Healthcare Fund II, L.P.
Who are the main parties involved in this filing?
The filing involves James Huang, Panacea Venture Healthcare Fund II, L.P. (and its GP Company, Ltd.), and the subject company, Connect Biopharma Holdings Limited.
What is the new ownership percentage reported?
The filing reports that the group beneficially owns 10,000,000 ordinary shares, representing approximately 10.1% of the outstanding shares.
When was the previous amendment filed?
The filing references a previous amendment filed on June 28, 2024.
What is the business address of Connect Biopharma Holdings Limited?
The business address is 12265 El Camino Real, Suite 350, San Diego, CA 92130.
Filing Stats: 1,613 words · 6 min read · ~5 pages · Grade level 10.5 · Accepted 2024-07-01 16:16:48
Key Financial Figures
- $0.000174 — ating to the Ordinary Shares, par value $0.000174 per share (the Ordinary Shares) of Conn
- $1.5303 — sactions at a weighted average price of $1.5303 per American Depositary Share. Panacea
Filing Documents
- d840148dsc13da.htm (SC 13D/A) — 93KB
- 0001193125-24-173301.txt ( ) — 94KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : July 1, 2024 Panacea Innovation Limited By: /s/ James Huang Name: James Huang Title: Founding Managing Partner Panacea Venture Healthcare Fund II, L.P. By: Panacea Venture Healthcare Fund II GP Company, Ltd., its general partner By: Panacea Innovation Limited, its sole owner By: /s/ James Huang Name: James Huang Title: Founding Managing Partner Panacea Venture Healthcare Fund II GP Company, Ltd. By: Panacea Innovation Limited, its sole owner By: /s/ James Huang Name: James Huang Title: Founding Managing Partner James Huang /s/ James Huang